Journal of Diabetes and Metabolic Disorders最新文献

{"title":"Non-blood type O is associated with an increased likelihood of gestational diabetes development: findings from an updated meta-analysis.","authors":"Raphael Enrique Tiongco, Miljun Catacata, Pia Vanessa Basilio, Eliezer John Castro, Benjie Clemente, Raenard Emmanuel Dayrit, Michelle Charina Gomez, Michael John Dominguez, Shamar Lo Lasta, Jefferyl Kae Pandac, Maria Ruth Pineda-Cortel","doi":"10.1007/s40200-025-01653-1","DOIUrl":"10.1007/s40200-025-01653-1","url":null,"abstract":"<p><strong>Purpose: </strong>Several factors are attributed to the development of gestational diabetes mellitus (GDM), but its association with the ABO blood group is still unexplored. Hence, we performed a meta-analysis to examine this association.</p><p><strong>Methods: </strong>Relevant articles were obtained from various databases until April 5, 2025. All related data were extracted by two authors and summarized in a customized spreadsheet. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed and interpreted.</p><p><strong>Results: </strong>The pooled analysis showed homogeneity in the outcomes. Pooled ORs show that pregnant women with non-blood type O showed more significant associations than those with blood type O.</p><p><strong>Conclusion: </strong>Overall, the present meta-analysis suggests that individuals with non-blood type O have an increased risk of developing GDM compared to those with blood type O. However, further studies stratifying populations based on insulin resistance, gut microbiota, and inflammation in association with ABO and GDM development are needed to confirm these claims.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01653-1.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"133"},"PeriodicalIF":1.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing diabetes care: the role of artificial intelligence in prevention, diagnosis, and patient care.","authors":"Madhav Kohli, Pallavi Pandey, Vikash Jakhmola, Supriyo Saha, Meenu Chaudhary, Arif Nur Muhammad Ansori, Arvind Negi","doi":"10.1007/s40200-025-01648-y","DOIUrl":"10.1007/s40200-025-01648-y","url":null,"abstract":"<p><p>Millions of people worldwide have diabetes, a disease that is becoming more common and has substantial socioeconomic costs. Artificial intelligence (AI) improves diabetes management, diagnosis, and prevention. AI-powered tools enable early detection of diabetes and its complications, including diabetic retinopathy, using sophisticated algorithms and large-scale data analysis. Wearable devices and continuous glucose monitors, integrated with AI, facilitate personalized treatment plans and real-time insights, improving glycemic control and overall health outcomes. Advanced machine learning models demonstrate high accuracy in diagnosing and predicting diabetes, while automated insulin delivery systems and bolus calculators enhance insulin management, reducing risks of hypo- and hyperglycemia. Despite these advancements, challenges such as cost, accessibility, device interoperability, and ethical considerations persist. The development of new digital biomarkers, individualized clinical metrics, and patient-centric solutions is critical for optimizing care. While AI holds immense promise in alleviating the global diabetes burden, addressing these limitations through sustained innovation and collaboration is essential. This review underscores the transformative potential of AI in revolutionizing diabetes care, enabling advancement for enhanced prevention, precise diagnosis, and effective management strategies.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01648-y.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"132"},"PeriodicalIF":1.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, efficacy and psychological impact of Omnipod hybrid closed loop system in children, adolescents, and adults in 24 h and nighttime: Systematic review with additional meta-analysis.","authors":"Rahma Mogahed Rateb, Ismael Abdullah Kareem, Ahlem Nour El Yakine Bounechada, Lyna Delhoum, Fadi Qasim Altamimi, Sara Aljawamis, Aya Helmy Aboelyazid","doi":"10.1007/s40200-025-01639-z","DOIUrl":"10.1007/s40200-025-01639-z","url":null,"abstract":"<p><strong>Background: </strong>Automated insulin delivery has been developed with various algorithms and designs. Omnipod 5 is the latest Commercially available device. We aimed to explore the safety efficacy and psychological impact of the new Omnipod hybrid closed-loop system.</p><p><strong>Methods: </strong>We used PubMed, Google Scholar, Scopus, Web of Science, and Cochrane Library for our search, we analyzed pre and post-data for continuous glucose monitoring data and HbA1C using RevMan software. When we observed heterogeneity, we used random effect model otherwise fixed effect model was used. We addressed heterogeneity using leave-one-out sensitivity analysis. We performed subgroup analysis based on study design and age subgroups. We reported outcomes that couldn't be analyzed narratively.</p><p><strong>Results: </strong>Out of 12 studies with 13 reports, we analyzed pre and post-data of eight studies. Pooled data of 665 patients showed significant improvement in time in range 70-180mg/dl [MD 11.30% [95% CI: 9.75 to 12.84], P < 0.00001]. Time above range 180mg/dl was significantly improved [MD -9.88% [95% CI: -11.52 to -8.25], P < 0.00001]. Among six trials nighttime time below range 70mg/dl showed significant results TBR [MD -2.6% [95%CI: -3.77 to -1.44], p < 0.0001] with Considerable heterogeneity that was fixed by sensitivity analysis. Omnpod hybrid closed loop [HCL] showed improvement in type 1 diabetes distress score which is consistent among reported studies.</p><p><strong>Conclusion: </strong>Post Omnipod HCL usage showed improvement in 24h and nighttime which needs confirmation with more evidence.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01639-z.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"134"},"PeriodicalIF":1.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<b>Diabetes-induced depression: unravelling the role of gut dysbiosis</b>.","authors":"Vivek Kumar Sharma","doi":"10.1007/s40200-025-01643-3","DOIUrl":"10.1007/s40200-025-01643-3","url":null,"abstract":"<p><p>Depression is a prevalent yet often underdiagnosed neuropsychiatric comorbidity of type 2 diabetes mellitus (T2DM), significantly complicating disease management, treatment adherence, and overall well-being. Emerging evidence suggests that gut microbiota dysbiosis plays a pivotal role in linking T2DM and depression through mechanisms such as epithelial barrier dysfunction, systemic inflammation, neurotransmitter imbalances, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, and impaired neurogenesis. This review aims to explore the mechanistic pathways through which diabetes-induced dysbiosis contributes to depression and to appraise the therapeutic potential of microbiota-targeted interventions, including probiotics, prebiotics, and fecal microbiota transplantation, in mitigating depressive symptoms and improving metabolic outcomes. Understanding this gut-brain interplay may provide novel insights into therapeutic strategies for managing the dual burden of diabetes and depression.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"129"},"PeriodicalIF":1.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in diabetes research and stem cell therapy: a concise review.","authors":"Ashlyn Wen Ning Yau, Adeline Yoke Yin Chia","doi":"10.1007/s40200-025-01638-0","DOIUrl":"10.1007/s40200-025-01638-0","url":null,"abstract":"<p><p>Diabetes mellitus, encompassing both T1DM and T2DM, represents a global health challenge. While traditional therapies focus on managing symptoms, emerging stem cell therapies, particularly MSCs, offer potential curative approaches. This review explores advancements in diabetes research with an emphasis on mesenchymal stem cells (MSCs). Additionally, we discuss clinical trials and applications of MSCs in diabetes treatment, providing a comprehensive analysis of this promising therapeutic frontier. MSCs have been shown to provide immunomodulatory effects, delay disease progression and reverse insulin resistance in preclinical and clinical studies. MSC-derived EVs have been extensively studied as well, exhibiting similar therapeutic benefits while also possibly having lower immunogenicity than MSCs. Phase I and II clinical studies have demonstrated MSCs to be effective in juvenile T1DM and able to significantly reduce HbA1c, fasting blood glucose, insulin demand and plasma blood glucose levels (<i>p</i> < 0.05). There is however a lack of standardisation of protocols across studies, highlighting the need for comparative studies to establish the optimal dosing, treatment schedule, administration route and source of MSCs. Large-scale randomised controlled trials are necessary to establish safety and efficacy in human patients, paving the way for MSC-based therapies in diabetes treatment. <b>Clinical trial number</b>: Not applicable.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"130"},"PeriodicalIF":1.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilizing the healing power of flaxseed: a narrative review of its therapeutic applications.","authors":"Niyoosha Mohammadkhani, Mahdis Moradnia, Mehdi Mohammadi, Sholeh Ebrahimpour, Ozra Tabatabaei-Malazy, Somayeh Mirsadeghi, Hamid Akbari Javar","doi":"10.1007/s40200-025-01636-2","DOIUrl":"10.1007/s40200-025-01636-2","url":null,"abstract":"<p><strong>Purpose: </strong><i>Linum usitatissimum</i> L. (flaxseed), an herbaceous plant from the Linaceae family, possesses antioxidant and anti-inflammatory properties, making it effective in treating various health conditions. Although numerous studies have explored the benefits of flaxseed, a comprehensive review of its antioxidative and anti-inflammatory effects is lacking. Such a review would provide a clearer perspective on its medical applications. This study aims to comprehensively examine these effects based on research conducted on the management of various disorders.</p><p><strong>Method: </strong>We conducted a narrative review of flaxseed and its derivatives by systematically searching for the keywords \"<i>Linum usitatissimum</i> L., flax, flaxseed, antioxidant<i>\"</i>, and \"anti-inflammatory, oxidative stress, inflammation, herbal medicine, nutraceuticals, cytokines<i>\"</i> in reputable international databases, including PubMed, Web of Science, the Cochrane Library, and Scopus, up until October 1, 2024. A total of 2,412 articles were reviewed, of which 2,336 were excluded due to duplication, irrelevance or similarity. The findings were categorized into in vitro, animal, and clinical studies.</p><p><strong>Results: </strong>Numerous studies indicate that flaxseed and its derivatives reduce inflammatory cytokine levels. Additionally, they exhibit antihyperlipidemic, antihyperglycemic, and cardioprotective properties due to their antioxidative and anti-inflammatory effects. Furthermore, animal and clinical studies suggest that flaxseed extract reduces body fat storage and insulin resistance while offering various therapeutic benefits.</p><p><strong>Conclusion: </strong>In conclusion, various studies demonstrate the significant potential of flaxseed for prevention and management of diseases. Its efficacy is likely attributable to its antioxidative and anti-inflammatory properties. However, further research is required to fully understand its therapeutic potential.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"128"},"PeriodicalIF":1.8,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of costs related to health services in two groups of patients with diabetic foot ulcer and patients without this complication: a matched cohort study.","authors":"Zhila Najafpour, Tahereh Rashidi, Maryam Seyedtabib, Leila Yazdanpanah","doi":"10.1007/s40200-025-01637-1","DOIUrl":"10.1007/s40200-025-01637-1","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic foot ulcer (DFU) is a serious complication of diabetes that significantly increases healthcare expenditure worldwide. The aim of this study is to calculate the average costs for patients with and without DFU over a nine-month period.</p><p><strong>Methods: </strong>This cost-of-illness study comprised 480 patients, including 160 cases (with DFU) and 320 controls (diabetes only), matched 1:2 by age (± 5 years) and sex. Direct and indirect medical costs were collected over a nine-month period using a questionnaire. We used the Mann-Whitney U test for continuous variables and the Pearson chi-square test for categorical variables. The GLM was also used to predict costs based on demographic and clinical factors. All statistical analyzes were performed using SPSS with a significance level of p < 0.05.</p><p><strong>Results: </strong>The average total direct medical costs (inpatient and outpatient) were PPP$ 3,493.64 (SD: 2,714.66) for the DFU group and PPP$ 1,353.44 (SD: 110.85) for the diabetes-only group. Medication expenditures were the highest outpatient costs in the DFU group, with a mean of PPP$ 1,079.59 (SD: 247.13) (P < 0.001). Mean transportation costs in the DFU group were PPP$ 299.66 (SD: 240.49), compared with PPP$ 96.01 (SD: 7.83) in the control group. The mean indirect costs were PPP$ 2,256.31 (SD: 1,332.39) for the DFU group and PPP$ 100.78 (SD: 24.63) for the control group. Patients with more advanced ulcer stages (B = 9050.275, p < 0.05) and with middle education levels (B = 208.77, p < 0.05) had significantly higher costs. In contrast, retired individuals had significantly lower costs (B = -459.77, p < 0.05).</p><p><strong>Conclusions: </strong>Patients with DFU incur substantially higher direct and indirect costs compared to those with diabetes alone. Medication and other service utilization-including blood glucose self-monitoring and consumables such as test strips, blood glucose meters, lancets, and syringes-are key contributors to outpatient expenses. The elevated indirect costs in DFU patients primarily reflect lost productivity. These higher overall costs are largely driven by the severity of the complication. Optimizing treatment strategies to prevent disease progression and avoid costly complications is essential for reducing the financial burden associated with DFU.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"127"},"PeriodicalIF":1.8,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression and clinical significance of mir-520g-3p in patients with gestational diabetes mellitus.","authors":"Yi Ding, Min Cai, Yan Wang, Runpeng Zhao, Xin Yue","doi":"10.1007/s40200-025-01629-1","DOIUrl":"10.1007/s40200-025-01629-1","url":null,"abstract":"<p><strong>Background: </strong>Gestational diabetes mellitus (GDM) is a metabolic disorder characterized by glucose intolerance that develops during pregnancy. Recent studies have begun to elucidate the role of MicroRNAs (miRNAs) in the pathophysiology of GDM, suggesting that these non-coding RNAs could serve as potential biomarkers for the condition. This study aimed to investigate the clinical diagnostic value of miR-520g-3p in GDM patients.</p><p><strong>Methods: </strong>GSE104297 dataset was downloaded and analyzed by R software to obtain the differentially expressed miRNAs. A total of 110 GDM patients and 110 healthy pregnant women were recruited and the serum samples were collected. The expressions of miRNAs in the serum samples were detected by qRT-PCR assay. Then, the diagnostic value of miR-520g-3p in GDM patients were analyzed by receiver operating curve (ROC) analysis. The correlation between miR-520g-3p expression and patient clinical information was analyzed using Pearson analysis.</p><p><strong>Results: </strong>Through the GSE104297 dataset, we obtained a total of 15 upregulated and 15 downregulated miRNAs in the feto-placental endothelial cells of GDM patients. Then, in the serum of GDM patients, miR-520g-3p, miR-519d-3p, miR-145-3p, miR-1246 and miR-671-3p expression levels were significantly increased, while miR-579-3p and miR-378a-5p were decreased. Among them, the change in miR-520g-3p is the most significant. Furthermore, the results of ROC analysis showed that the AUCs of miR-520g-3p in GDM patients from normal pregnant women were 0.861. miR-520g-3p levels was significantly positively correlated with FBG, OGTT (1 h and 2 h) and TG.</p><p><strong>Conclusion: </strong>This study identifies miR-520g-3p might be a promising biomarker for GDM, demonstrating significant correlations with clinical characteristics and diagnostic potential.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"126"},"PeriodicalIF":1.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case series of bilateral inferior petrosal sinus sampling using desmopressin for evaluation of ACTH-dependent cushing's syndrome in pediatric patients: insights from Iran.","authors":"Majid Valizadeh, Fatemeh Rahmani, Mohammad Nikoohemmat, Arash Khameneh Bagheri, Behnaz Abiri","doi":"10.1007/s40200-025-01634-4","DOIUrl":"10.1007/s40200-025-01634-4","url":null,"abstract":"<p><strong>Background: </strong>Pediatric Cushing Syndrome (CS) is rare and difficult to diagnose, especially when distinguishing ACTH-dependent subtypes. Bilateral inferior petrosal sinus sampling (BIPSS) is an essential but technically challenging procedure for this purpose. Because corticotropin-releasing hormone (CRH), the standard stimulant, has limitations, desmopressin is being explored as an alternative. This study assesses desmopressin-stimulated BIPSS for its diagnostic accuracy and tumor localization in pediatric CS within an Iranian cohort, addressing a gap in pediatric-specific diagnostic strategies and offering insights into the applicability of desmopressin in this context.</p><p><strong>Methods: </strong>Four pediatric patients with inconclusive pituitary imaging and suspected Cushing's disease (CD) underwent BIPSS with desmopressin at Taleghani Hospital, Tehran, Iran, between August 2015 and March 2019. Sensitivity of BIPSS for CD diagnosis was assessed, and tumor localization accuracy was evaluated during surgery.</p><p><strong>Results: </strong>Bilateral IPSS demonstrated a sensitivity of 100% for diagnosing CD in pediatric patients. However, accuracy for tumor lateralization was moderate, with only 50% concordance between BIPSS lateralization and surgical findings. Specifically, two out of four patients had correct lateralization confirmed during surgery, while one patient with left lateralization was consistent with hypophysectomy findings. These discrepancies highlight challenges such as anatomical and drainage variations that can lead to mislocalization.</p><p><strong>Conclusion: </strong>Desmopressin enhances the sensitivity of BIPSS for diagnosing pediatric CD, presenting as a viable alternative to CRH stimulation. Despite high sensitivity, caution is advised when interpreting BIPSS results for tumor localization. Further research is needed to optimize diagnostic strategies for pediatric CS management.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"125"},"PeriodicalIF":1.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive risk analysis of diabetic peripheral neuropathy in type II diabetes mellitus.","authors":"Alex Contesa, Hema Malini, Dally Rahman","doi":"10.1007/s40200-025-01630-8","DOIUrl":"10.1007/s40200-025-01630-8","url":null,"abstract":"<p><strong>Objective: </strong>Type II diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia resulting from impaired insulin secretion, action, or both. Diabetic peripheral neuropathy is among the most common complications of disease, with its incidence linked to various risk factors. This study aims to evaluate the risk factors associated with peripheral neuropathy among patients with Diabetes Mellitus in Padang City.</p><p><strong>Method: </strong>Using a descriptive, cross-sectional design with stratified random sampling, 390 T2DM patients were assessed. Research instruments included the Global Physical Activity Questionnaire, the Patient Health Questionnaire-9, and the Michigan Neuropathy Screening Instrument. Data analysis employed chi-square tests and multiple logistic regression.</p><p><strong>Results: </strong>The findings revealed significant associations between Diabetic peripheral neuropathy and factors such as diabetes duration, socioeconomic status, smoking, glycemic control, dyslipidemia, physical activity, and depressive symptoms (<i>p</i> < 0.05). Conversely, no significant relationship was observed for sex or hypertension (<i>p</i> > 0.05). Dyslipidemia emerged as Diabetic peripheral neuropathy's most influential risk factor (<i>p</i> = 0.000, OR = 3.295).</p><p><strong>Conclusion: </strong>This study emphasizes the importance of early detection through routine screening and regular follow-up care. Targeting modifiable risk factors through health education and improved disease management strategies could significantly reduce the burden of Diabetic peripheral neuropathy among Type 2 Diabetes Mellitus patients.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"123"},"PeriodicalIF":1.8,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}